Sidong Li / nature - Nature Medicine, Published online: 09 March 2026; doi:10.1038/s41591-026-04239-3In a prespecified ancillary analysis of the COSMOS randomized trial, supplementation with daily multivitamins, but not with cocoa extract, over the course of 2 years decreased…
#healthcare #publichealth #researchfunding
Monday, March 9, 2026, 6:24 pm / permalink 20417 / 6 stories in 7 days
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Monday, March 9, 2026, 4:22 am / permalink 20364 / 18 stories in 7 days
medicalxpress - A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed those medications nationwide, a…
#healthcare #pharmaceuticals #publichealth #governmentpolicy #infanthealth #hospitaloperations
Monday, March 9, 2026, 12:22 am / permalink 20354 / 4 stories in 7 days
fiercehealthcare - The deal, effective March 3, includes 126 physicians and advanced practitioners, expanding the academic system's primary care capacity.
#healthcare #mergersandacquisitions #corporatetakeover #hospitaloperations #healthcarefinance
Monday, March 9, 2026, 12:22 am / permalink 20353 / 7 stories in 7 days
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours
AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: